Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL<sup>pro</sup> Inhibitors
The 3C-like protease (3CL<sup>pro</sup>) of SARS-CoV-2 is considered an excellent target for COVID-19 antiviral drug development because it is essential for viral replication and has a cleavage specificity distinct from human proteases. However, drug development for 3CL<sup>pro<...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/2/173 |